| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6831b19bfc354357342f7c7da79fc162 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42 |
| filingDate |
1991-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80548ab4a6277626d3aa47b14f098215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_673121aaeb2ef60b15b215fcd2720090
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c92eff27a27feebfdb35076bf394ffdc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f004b292255a88a1d9b1906063935699 |
| publicationDate |
1993-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H0597670-A |
| titleOfInvention |
Preparation for oral administration |
| abstract |
(57) [Summary] [Structure] General formula (However, R is a phenyl group or naphthyl group which may have a substituent, and Alk is a lower alkylene group.) As an active ingredient, an ultrafine powder of a benzoxazole derivative or a pharmaceutically acceptable salt thereof is used. A formulation for oral administration containing. [Effect] It has a stable and high bioavailability for effectively exerting the drug effect of the above-mentioned benzoxazole derivative, and is excellent as an oral administration preparation for treating diabetes. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005105109-A1 |
| priorityDate |
1991-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |